Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?

@article{Vis2015RiskOD,
  title={Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?},
  author={Andr{\'e} N. Vis and Tim M van der Sluis and Hoda H M Al-Itejawi and R Jeroen A van Moorselaar and Eric Johan H Meuleman},
  journal={Urologic oncology},
  year={2015},
  volume={33 1},
  pages={
          7-15
        }
}
OBJECTIVES The traditional assumption of a linear relationship between serum testosterone and prostate cancer growth has been seriously challenged, as overwhelming evidence contradicts its basic principles. Luteinizing hormone-releasing hormone (LHRH) agonists are known to cause a peak in serum testosterone level in the initial weeks of treatment, and prevention of the clinical sequelae of testosterone flare by concomitant use of antiandrogens is recommended. Along the present biological… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

Similar Papers

Loading similar papers…